Daewoong & Dong-A ST succeeded in avoiding one of two patents of Otezla (Apremilast), a psoriasis treatment drug worth ₩2.46 trillion in global sales.

While Amgen, the original company, has yet to officially release Otezla in Korea, the two companies are on the verge of releasing generics early. According to the pharmaceutical industry on the 26th, the Intel Property Trial and Appeal recently ruled in a passive right-checking trial on Otezla's patent filed by Daewoong and Dong-A ST against Amgen.

There are two patents, use patent, which expires in March 2028, and formulation patent, which expires in December 2032.

The patents avoided by Daewoong and Dong-A ST are f